Super-BEAM for Myeloma – pro

BEAM Super is a 9 high dose chemo drugs over 5 days chemo regime. It is unique to the University of Arkansas Myeloma center. The regimen comprises BCNU at 300mg/m2 on day 1, etoposide 200mg/m2 on days 1-4; cytarabine 400mg/m2 on days 1-5; melphalan 140mg/m2 on day 5 plus: bortezomib 1.0-1.3mg/m2 on days 1+4, thalidomide 100-200mg on days 1-5, dexamethasone 20-40mg days 1-5, cisplatin 10-12.5mg/m2/d by continuous infusion on days 1-5, rapamycin 3mg on day 1 and 1mg on days 2-5; followed by autotransplant (AT) on day 6.

This is relatively unpublished regimen, although it is in extensive use at University of Arkansas. In general, conditioning regimens have been established on the basis of phase II studies; there are only few comparative studies of different conditioning regimen. This Super-BEAM regimen is ahead of the “curve” and should be considered experimental. Very little had been published on it as of yet.

Imrie K, Rumble RB, Crump M, Advisory Panel on Bone Marrow and Stem Cell Transplantation, Hematology Disease Site Group. Stem cell transplantation in adults: recommendations. Toronto (ON): Cancer Care Ontario Program in Evidence-based Care; 2009 Jan 30.78 p. (Recommendation report; no. 1).  [66 references]

Sarah Waheed, MD et al, abs3421 SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM)
Poster Session: Clinical Results – Autologous Transplantation Poster III
ASH 2009 myeloma 2012

Read the Layperson version here.

Participate in our Forums

To ask questions or participate in a discussion, please visit our Forums. You must LOGIN to participate.

Help Us Help Others

You can become a Site Sponsor. Or you may wish to support our work with a Donation.

Focused Articles For You

Lay Portal